TECH · Bio-Techne Corporation

Bio-Techne’s Q3 FY2026 results reflect a divergence between GAAP and Non-GAAP metrics: GAAP EPS more than doubled to $0.32, driven by a 95% surge in GAAP operating income to $75.5M — largely attributable to the Exosome Diagnostics divestiture and absence of a $38.9M litigation charge incurred in the prior-year quarter. However, adjusted EPS declined to $0.53 from $0.56, and adjusted operating margin slipped to 34.2% from 34.9%, signaling underlying pressure from volume softness and unfavorable product mix across segments. Revenue fell 2% to $311.4M, with organic decline of 2% offset by favorable FX impact; management attributed the top-line weakness to lapping large prior-year GMP fast-track orders and timing delays in Commercial Supply shipments. Segment-wise, Protein Sciences ($226.2M, −1%) and Diagnostics & Spatial Biology ($85.6M, −4%) both reported declines, though the latter achieved 3% organic growth after excluding an 8% drag from its held-for-sale business. CEO Kim Kelderman highlighted continued double-digit growth from large pharma (sixth consecutive quarter) and stabilization in U.S. academic markets, while noting emerging biotech spending remains muted despite healthy funding — suggesting demand lag rather than fundamental deterioration. The declaration of a $0.08 quarterly dividend — unchanged from prior quarters — affirms ongoing capital return discipline but offers no signal of increased payout or buyback activity. With no forward guidance disclosed in the press release or 8-K, investors must rely on qualitative commentary about 'early indicators pointing to a more constructive outlook' and portfolio positioning across discovery, translational, and diagnostic applications.